Last mentioned: Mar 20, 2026
ASH Annual Meeting
Curis targets presentation of initial proof-of-concept data for the CLL study.
ASH Annual Meeting
Targeted presentation of initial proof-of-concept data for TakeAim CLL study.
Torrid Store Closures
Target date for an additional 30 store closures by Torrid to reach savings goals.
Q4 Earnings Release
Curis, Torrid, Caleres, and Lands' End all report Q4 2025 results.
Q4 Earnings Report
Reported $19.4M net income and updated clinical guidance for emavusertib.
PIPE Financing
Curis secured initial $20.2M in PIPE proceeds to fund oncology pipeline development.
PIPE Financing
Secured $20.2 million in initial proceeds with milestone-linked upside.
Erivedge Wind-down
Royalties from Erivedge began winding down, prompting the strategic sale to Oberland.
Erivedge Wind-down
Final Erivedge royalties received before the transition to Oberland.
Curis has transitioned to a pure-play oncology developer, leveraging a $27.2 million gain from the sale of Erivedge royalties to fund its emavusertib clinical programs. With a cash runway extended into 2027, the company is prioritizing its registrational study in lymphoma while reporting high MRD conversion rates in its AML triplet therapy.
Curis (CRIS) has successfully pivoted to a clinical-stage oncology focus, securing a cash runway into 2027 through a strategic asset sale and PIPE financing. Meanwhile, broader retail earnings from Torrid and Caleres reveal significant margin pressures from tariffs, signaling a complex macro environment for healthcare supply chains.